NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Z Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton- Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. Nat Med. 20 July 2015 [Epub ahead of print] doi: 10.1038/nm.3910
A new study published in Nature Medicine describes results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person’s own immune system to recognize and destroy cancer cells. The results demonstrated a clinical response in 80 percent of advanced multiple myeloma patients after undergoing autologous stem cell transplants (ASCT). This time, researchers modified T cells to attack cancer cells expressing NY-ESO-1, an antigen found in nearly 60 percent of multiple myelomas and previously shown to be associated with tumor growth and poor prognosis. Co-authors of the advance online publication include our own Drs. Carl June, Don Siegel, and Bruce Levine.
Read the Department of Communications news release.